Tempus AI, Inc. (TEM)

Market Cap	7.43B
Revenue (ttm)	693.40M
Net Income (ttm)	-746.33M
Shares Out	173.03M
EPS (ttm)	-6.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,076,247
Open	43.16
Previous Close	43.13
Day's Range	41.39 - 43.84
52-Week Range	22.89 - 91.45
Beta	n/a
Analysts	Buy
Price Target	61.22 (+42.6%)
Earnings Date	May 17, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Jun 14, 2024
• Employees: 2,400
• Stock Exchange: NASDAQ
• Ticker Symbol: TEM
• Website: https://www.tempus.com

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD

Analyst Forecast

According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $61.22, which is an increase of 42.60% from the latest price.

Price Target

$61.22

(42.60% upside)

Analyst Consensus: Buy